Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,573 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Completed Phase 2 Interventional Results available

Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant

NCT00321932
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis, Ovarian Cancer
Interventions
calcium, cholecalciferol, zoledronic acid
Dietary Supplement · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 25, 2026, 11:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults

NCT02057263
View directory record Official record
Conditions
Hepatitis B
Interventions
Alendronate, Hepatitis B Vaccine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 25, 2026, 11:53 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Leptin Replacement Therapy in Patients With Lipodystrophy

NCT00896298
View directory record Official record
Conditions
Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy, Insulin Resistance
Interventions
Leptin, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 25, 2026, 11:53 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Ortho-R® for Rotator Cuff Repair Compared With Standard of Care Rotator Cuff Repair Without Ortho-R®

NCT05333211
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Ortho-R/PRP
Drug
Lead sponsor
ChitogenX Inc
Industry
Eligibility
40 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Lauderdale, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 25, 2026, 11:53 PM EDT
Terminated Phase 2 Interventional

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

NCT05359133
View directory record Official record
Conditions
Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Interventions
Tetrodotoxin, Placebo
Drug
Lead sponsor
Wex Pharmaceuticals Inc.
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Santa Ana, California • Santa Rosa, California • Port Charlotte, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 25, 2026, 11:53 PM EDT
Recruiting Not applicable Interventional

Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser

NCT07718347
View directory record Official record
Conditions
Immediate Post-Treatment Care, Aging Mid-Face, Aging
Interventions
ariessence pure PDGF+™ is a sterile aqueous formulation containing Hyaluronic Acid and pure platelet-derived growth factor (PDGF).
Other
Lead sponsor
Lynch Regenerative Medicine
Network
Eligibility
40 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Sacramento, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 25, 2026, 11:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Trauma Management Therapy for OEF and OIF Combat Veterans

NCT02809326
View directory record Official record
Conditions
Post-Traumatic Stress Disorder, Combat Disorders
Interventions
17 week Exposure Therapy Control Arm, Trauma Management Therapy, Intensive 3-Week Trauma Management Therapy
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 25, 2026, 11:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction

NCT01220726
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botox, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 25, 2026, 11:53 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

NCT03608033
View directory record Official record
Conditions
IgA Nephropathy
Interventions
OMS721, Vehicle (D5W or saline)
Biological · Other
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
34
States / cities
Florence, Alabama • Mesa, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 25, 2026, 11:53 PM EDT
Completed Not applicable Interventional

Juvenile Justice Girls Randomized Control Trial: Young Adult Follow-up

NCT01341626
View directory record Official record
Conditions
Delinquency, Drug Use
Interventions
Treatment Foster Care (TFCO), Group Care
Behavioral
Lead sponsor
Oregon Social Learning Center
Other
Eligibility
13 Years to 18 Years · Female only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2016
U.S. locations
2
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 25, 2026, 11:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels

NCT01770743
View directory record Official record
Conditions
Anthrax
Interventions
AV7909, BioThrax
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 50 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Miami, Florida • Mt. Pleasant, South Carolina • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 25, 2026, 11:53 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Circulating and Tissue-specific Lipids on Vascular Function and Insulin Sensitivity in Chronic Night Shift Workers

NCT06550115
View directory record Official record
Conditions
Circadian Rhythm Sleep Disorder of Shift Work Type, Metabolic Disease, Insulin Sensitivity, Blood Pressure
Interventions
Time-restricted eating, Control eating
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 25, 2026, 11:53 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Green Tea and Tai Chi for Bone Health

NCT00625391
View directory record Official record
Conditions
Osteoporosis
Interventions
Placebo, Green Tea Polyphenols (GTP), Placebo+Tai Chi (TC), GTP+TC
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
Female only
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 25, 2026, 11:53 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

NCT04579588
View directory record Official record
Conditions
Corona Virus Infection, Flu Vaccine, Immunity
Interventions
Flu shot
Biological
Lead sponsor
Stanford University
Other
Eligibility
9 Years to 64 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 25, 2026, 11:53 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation

NCT05790941
View directory record Official record
Conditions
Hypotrichosis
Interventions
Latanoprost and Minoxidil
Combination Product
Lead sponsor
Aneira Pharma, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Indian Wells, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 25, 2026, 11:53 PM EDT
Completed Phase 2 Interventional Results available

Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx

NCT00071890
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin 2, HAART, Treatment interruption
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Oct 25, 2026, 11:53 PM EDT
Completed Not applicable Interventional Results available

Smoking Cessation Using Motivational Therapy and Varenicline

NCT00701896
View directory record Official record
Conditions
Smoking, HIV Infections
Interventions
Varenicline tartrate, Nicotine Replacement Therapy, Biological Control, Motivational Interview
Drug · Other · Behavioral
Lead sponsor
Philip Diaz
Other
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 25, 2026, 11:53 PM EDT
Completed Phase 3 Interventional

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

NCT00039013
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
129
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 25, 2026, 11:53 PM EDT
Not listed Phase 2 Interventional

Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia

NCT04373941
View directory record Official record
Conditions
Biliary Atresia
Interventions
Filgrastim
Drug
Lead sponsor
Holterman, Ai-Xuan, M.D.
Individual
Eligibility
14 Days to 180 Days
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 25, 2026, 11:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Thrombolytic Care During Inter-hospital Transfer

NCT02752256
View directory record Official record
Conditions
Stroke
Interventions
Tissue Plasminogen Activator
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 25, 2026, 11:53 PM EDT
Active, not recruiting Early Phase 1 Interventional

Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix

NCT03305341
View directory record Official record
Conditions
Covid19
Interventions
COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use
Biological
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Industry
Eligibility
24 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
North Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 25, 2026, 11:53 PM EDT
Completed Phase 2 Interventional

Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation

NCT00949754
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
honeybee venom (Apitoxin (Korea) Apitox (USA))
Drug
Lead sponsor
Apimeds, Inc.
Industry
Eligibility
35 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Pinellas Park, Florida • Chicago, Illinois • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2010 · Synced Oct 25, 2026, 11:53 PM EDT
Not listed Phase 2 Interventional

Dose-Finding Study of SC411 in Children With Sickle Cell Disease

NCT02973360
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Docosahexaenoic Acid, Placebo
Drug
Lead sponsor
Micelle BioPharma Inc
Industry
Eligibility
5 Years to 17 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Oakland, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 25, 2026, 11:53 PM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

NCT03376477
View directory record Official record
Conditions
Multiple Myeloma
Interventions
GM-CSF vaccine, Lenalidomide, Prevnar13, Placebo Prevnar13, Placebo GM-CSF Vaccine
Biological · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 25, 2026, 11:53 PM EDT